Loading...
•
Jun 30, 2021
Cencora Q3 2021 Earnings Report
Reported revenue increased by 17.7% year-over-year, with GAAP diluted EPS at $1.40 and adjusted diluted EPS at $2.16.
Key Takeaways
AmerisourceBergen Corporation reported a 17.7% increase in revenue to $53.4 billion for the third quarter of fiscal year 2021. The company's GAAP diluted EPS was $1.40, while adjusted diluted EPS increased to $2.16. The company has raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $9.15 to $9.30.
Revenue increased by 17.7% year-over-year to $53.4 billion.
GAAP diluted EPS was $1.40 for the quarter.
Adjusted diluted EPS increased 16.8% to $2.16.
Adjusted diluted EPS guidance raised to $9.15 to $9.30 for fiscal year 2021.
Cencora
Cencora
Forward Guidance
AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted average shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance Healthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the Company delivered to Walgreens at the closing of the transaction. AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company’s continued strong performance across its businesses.
Positive Outlook
- Adjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.
- Adjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range.
- Adjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range.
- Pharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from growth in the high-single digit percent range.
- Adjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.